Selecting First-line ART in Treatment-Naive Persons With HIV
Learn about ART selection in treatment-naive PWH based on the latest guideline recommendations through case-based discussions by Princy N. Kumar, MD, FIDSA, MACP.
Decera Clinical Education Infectious Disease Podcast · Princy N Kumar MD FIDSA MACP
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Princy N. Kumar, MD, FIDSA, MACP, discusses key considerations for selecting ART in treatment-naive persons with HIV. Her discussion includes:
- DHHS Treatment Guideline recommendations
- Choosing among first-line recommended integrase inhibitors
- Recommended regimens for rapid ART start
- Select key studies in treatment-naïve adults:
- AMBER study of virologic response with DRV/COBI/FTC/TAF vs DRV/COBI + TFC/TDF
- DRIVE-AHEAD and DRIVE-FORWARD efficacy study results, including resistance analyses of DOR + 2 NRTIs vs EFV or (DRV + RTV) + 2 NRTIs
- Safety and efficacy results from GEMINI-1 and GEMINI comparing DTG + 3TC vs DTG + FTC/TDF
- The current/possible role of boosted PIs and NNRTIs
- Selection considerations between TDF and TAF
Presenter:
Princy N. Kumar, MD, FIDSA, MACP
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3VIsDTg
Follow along with the slides:
https://bit.ly/3PYy1zn
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.